A Phase II, Randomized, Multi-centre, Double-blind, Parallel-group, Dose-ranging, Exploratory Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476 (Mesalazine) Once Daily
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007251/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Evaluate the percentage of subjects in remission at the end of an 8-week treatment period for
three dose groups (SPD476 1.2 g/day, 2.4 g/day or 4.8 g/day, administered once daily).
提供机构：
Vivli
创建时间：
2021-07-01
